EPZMUnknown
Epizyme, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Epizyme, Inc. (EPZM), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are EPZM insiders buying or selling?
Epizyme, Inc. insiders reported 5 open-market buys ($39.3M) and 46 sells ($7.2M) across 51 Form 4 filings — a net buying position of $32.1M.
Source: SEC EDGAR Form 4
Key Statistics (as of Apr 13, 2022)
Total Form 4 filings
51
SEC EDGAR
Insider filers
10
Insider buys (5)
$39.3M
Insider sells (46)
$7.2M
Insider sentiment
Net buyingNet insider flow of $32.1M in net buying.
Recent EPZM insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 13, 2022 | Jeffery Kutok | Chief Scientific Officer | Sale | 2.7K | $0.90 | $2.5K |
| Feb 9, 2022 | Joseph Beaulieu | Corporate Controller | Sale | 222 | $1.50 | $333 |
| Feb 9, 2022 | Shefali Agarwal | Executive Vice President, Chief Medical and Development Officer | Sale | 1.1K | $1.50 | $1.6K |
| Feb 4, 2022 | Shefali Agarwal | Executive Vice President, Chief Medical and Development Officer | Sale | 2.6K | $1.37 | $3.6K |
| Feb 4, 2022 | Jeffery Kutok | Chief Scientific Officer | Sale | 2.6K | $1.37 | $3.5K |
| Feb 4, 2022 | Joseph Beaulieu | Corporate Controller | Sale | 687 | $1.37 | $941.19 |
| Feb 1, 2022 | Pablo G. Legorreta | Director, 10% Owner | Purchase | 22.7M | $1.50 | $34.0M |
| Jan 28, 2022 | Shefali Agarwal | Executive Vice President, Chief Medical and Development Officer | Sale | 2.9K | $2.02 | $5.9K |
| Dec 8, 2021 | Shefali Agarwal | Executive Vice President, Chief Medical and Development Officer | Sale | 1.8K | $2.93 | $5.2K |
| Apr 7, 2021 | Jeffery Kutok | Chief Scientific Officer | Sale | 2.0K | $8.80 | $17.9K |
| Mar 29, 2021 | David M Mott | Director | Purchase | 62.7K | $7.97 | $500.1K |
| Mar 29, 2021 | Robert B Bazemore | President & CEO | Sale | 10.3K | $7.85 | $81.1K |
| Feb 5, 2021 | Robert B Bazemore | President & CEO | Sale | 3.9K | $11.21 | $43.6K |
| Feb 5, 2021 | Shefali Agarwal | Chief Medical Officer | Sale | 969 | $11.21 | $10.9K |
| Feb 5, 2021 | Paolo Tombesi | Chief Financial Officer | Sale | 1.0K | $11.21 | $11.4K |
| Feb 5, 2021 | Joseph Beaulieu | Corporate Controller | Sale | 227 | $11.21 | $2.5K |
| Feb 5, 2021 | Matthew Ros | Executive Vice President, Chief Strategy & Business Officer | Sale | 894 | $11.21 | $10.0K |
| Feb 5, 2021 | Victoria Vakiener | Chief Commercial Officer | Sale | 817 | $11.21 | $9.2K |
| Jan 28, 2021 | Robert B Bazemore | President & CEO | Sale | 6.1K | $11.41 | $69.2K |
| Jan 28, 2021 | Matthew Ros | Executive Vice President, Chief Strategy & Business Officer | Sale | 2.9K | $11.41 | $32.8K |
| Jan 28, 2021 | Victoria Vakiener | Chief Commercial Officer | Sale | 599 | $11.41 | $6.8K |
| Jan 28, 2021 | Shefali Agarwal | Chief Medical Officer | Sale | 2.9K | $11.41 | $32.8K |
| Dec 7, 2020 | Shefali Agarwal | Chief Medical Officer | Sale | 2.5K | $13.54 | $34.1K |
| Nov 13, 2020 | Carl Goldfischer | Director | Purchase | 5.0K | $12.07 | $60.4K |
| Sep 4, 2020 | Joseph Beaulieu | Corporate Controller | Sale | 1.5K | $12.81 | $19.4K |
Showing the 25 most recent of 51 Form 4 filings for Epizyme, Inc..
Most active EPZM insiders
- Shefali Agarwal11 filings
- Joseph Beaulieu9 filings
- Matthew Ros8 filings
- Robert B Bazemore8 filings
- David M Mott5 filings
Ask anything about EPZM insider activity
Use Trabud's AI agent to query Epizyme, Inc.'s Form 4 history in plain English — "Show me EPZM CEO purchases this year" or compare it against any other ticker.
Open the AI agentEPZM insider trading FAQ
Are Epizyme, Inc. insiders buying or selling?
Across 51 SEC Form 4 filings, Epizyme, Inc. (EPZM) insiders reported 5 open-market purchases totaling $39.3M and 46 sales totaling $7.2M. That is a net buying position of $32.1M.
How many insiders trade EPZM stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Epizyme, Inc.. The most recent filing was accepted on Apr 13, 2022.
Where does Trabud get EPZM insider trading data?
All EPZM insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.